To investigate the underlying molecular mechanisms of the observed increased resistance of TP53-deficient AML cells to CAR T-cell attack, we performed gene expression analyses of resting anti-CD33 CAR T-cells as well as isogenic MOLM13-TP53−/− and MOLM13-TP53+/+ AML cells. This evidence concerns the gene TP53 and acute myeloid leukemia.